Concepedia

Jakub Żołnierek

JŻ

Statistics

Publications

15

Citations

3.4K

H-Index

13

Active since

2008

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

Memorial Sloan Kettering Cancer Center

Institut Gustave Roussy

Gdańsk Medical University

Wojskowy Instytut Medycyny Lotniczej

Jakub Żołnierek is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in medicine, oncology, and renal cell carcinoma.

ORCID

Publications per year

2008–2023

15

Publications

15

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

, , +9

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Robert J. Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology · 2015 · 943 citations · Full text

, , +14

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2014 · 263 citations · Full text

, , +12

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

Arkadiusz Z. Dudek, Jakub Żołnierek, Anu Dham et al. · Cancer · 2008 · 191 citations

, , +16

Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma — retrospective analysis

Wojciech Rogowski, Ewa Wachuła, Anita Gorzelak-Magiera et al. · Endokrynologia Polska · 2019 · 46 citations · Full text

, , +17

1–5 of 15